Dynamic quotes: Off
|
Company Description (as filed with the SEC)
NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and comprises a separate therapeutic technology platform in addition to the current three pillars of healthcare: pharmaceuticals, biologics and medical devices. Modern cell-based therapies have progressed from the first recorded human to human blood transfusion 200 years ago through to the advanced cellular therapies of today including bone marrow and organ transplantation, tissue banking and reproductive in vitro fertilization and future therapies being investigated to treat cancer, cardiologic, neurologic, ophthalmic and orthopedic diseases among others. ... More ...
Analyst Info |
|
| Annual EPS Est: | $999 |
| Quarterly EPS Est: | -0.05 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
1.25 |
Data is provided by Zacks Investment Research

